GWM
BHVN

Geneos Wealth Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Geneos Wealth Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$15K – 2136
2022
Q3 		$15K Hold
100
– – ﹤0.01% 1423
2022
Q2 		$14K Hold
100
– – ﹤0.01% 1848
2022
Q1 		$11K Sell
100
-3,000
-97% -$374K ﹤0.01% 2076
2021
Q4 		$427K Buy
3,100
+3,000
+3,000% +$381K 0.02% 631
2021
Q3 		$14K Hold
100
– – ﹤0.01% 2102
2021
Q2 		$9K Sell
100
-25
-20% -$2.03K ﹤0.01% 2264
2021
Q1 		$9K Hold
125
– – ﹤0.01% 2449
2020
Q4 		$6K Buy
125
+25
+25% +$2.12K ﹤0.01% 2445
2020
Q3 		$6K Hold
100
– – ﹤0.01% 2151
2020
Q2 		$7K Hold
100
– – ﹤0.01% 2064
2020
Q1 		$3K Hold
100
– – ﹤0.01% 2226
2019
Q4 		$5K Buy
+100
New +$4.95K ﹤0.01% 2213

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Geneos Wealth Management's BHVN Position: Q4 2022 in Review

Geneos Wealth Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 100 shares — an estimated $15K sold.

Geneos Wealth Management first reported a position in BHVN in Q4 2019 and held it in 12 quarters. The position peaked at $427K in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Geneos Wealth Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $15K.
  • Geneos Wealth Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 12 quarters.
  • Geneos Wealth Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $427K in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Geneos Wealth Management's 13F filing for Q4 2022, filed 31 Jan 2023.